ITMN – That’s a very interesting trial design. Although the clinicaltrials.gov entry shows six arms, there are effectively eight arms as follows:
Part 1:
1. ITMN-191 300mg TID + SoC; 24 or 48 weeks depending on RVR/EVR;
2. ITMN-191 600mg BID + SoC; 24 or 48 weeks depending on RVR/EVR;
3. ITMN-191 900mg BID + SoC; 24 or 48 weeks depending on RVR/EVR;
4. SoC only; 24 or 48 weeks depending on RVR/EVR.
Part 2:
5. ITMN-191 300mg TID + SoC; 24 weeks unconditionally;
6. ITMN-191 600mg BID + SoC; 24 weeks unconditionally;
7. ITMN-191 900mg BID + SoC; 24 weeks unconditionally;
8. SoC alone; 24 weeks unconditionally.
Arm #5 and, especially, arm #8 show a new willingness by the FDA to allow a shorter than 48-week duration of interferon + ribavirin to serve as a control arm, which I interpret as an admission by the FDA that the existing standard of 48 weeks of interferon + ribavirin is severely lacking.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”